The Alzheimer's Drug Discovery Foundation (ADDF) has invested more than $65 million to fund 450 drug research programs at academic centers and biotechnology companies in 18 countries. In 2013, we carried an active portfolio of 89 research grants.
Where We Fund
The ADDF is supporting some of the most promising and diverse research projects in the world. Currently, we are investing in researchers in Australia, Belgium, Canada, China, Finland, France, Germany, Israel, Italy, the Netherlands, Spain, Sweden, Switzerland, Taiwan, the United Kingdom and the United States.
What We Fund
The ADDF is focused on translating the knowledge we have gained about the underlying causes of Alzheimer’s disease into drugs. We fund programs in both academia and biotechnology companies worldwide, with priority funding in drug discovery and preclinical drug development, early detection, clinical trials and prevention.
What We've Accomplished
In 2012, the US Food and Drug Administration approved Amyvid™, the first-ever diagnostic test for Alzheimer's disesase, which was seed-funded by the ADDF. This successful technology is an important proof-of-concept for the ADDF model, showcasing how early financial support for high-risk projects can lead to and accelerate the development of innovative drugs and diagnostics in Alzheimer’s.
What's in the Pipeline
The pipeline graphic below highlights just a few of the 450 drug discovery programs supported by the ADDF, as well as follow-on funding garnered by these exciting research initiatives.